Analysts See 12% Upside To Thermo Fisher Scientific Inc. (TMO)

Recent expert updates see Wells Fargo lifting its terms people connected the banal to $675 from $635 connected December 15, citing accrued clarity astir the U.S. government’s policies connected the pharmaceutical industry, coupled with aboriginal maturation projections suggesting an upside.

The steadfast believes the concern is ripe for companies selling tools and equipment, and has kept its Overweight standing connected the stock.

This followed Citigroup’s update connected Thermo Fisher Scientific Inc. (NYSE:TMO) connected December 11, erstwhile it upgraded the stock’s standing to Buy from Neutral and hiked its terms people to $660 from $580.

The revision by Citi expert Patrick Donnelly was portion of the firm’s broader investigation for stocks successful the tools and diagnostics conception heading into 2026. The steadfast believes ongoing onshoring trends and accrued pharmaceutical spending volition payment the company.

Thermo Fisher Scientific Inc. (NYSE:TMO) is simply a starring supplier of beingness sciences solutions, laboratory products, diagnostics, analytical instruments, and biopharma services. The banal has had humble returns successful 2025, gaining 8% year-to-date.

While we admit the imaginable of TMO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 11 Most Oversold S&P 500 Stocks Heading into 2026 and Top 15 Lowest P/E Ratios of the S&P 500 successful 2025.

Disclosure: None.